Evidence map›Paper›PMID 42501279›Full record

ArticleApplied biochemistry and biotechnology2026

Computational Design of a Broad-Spectrum Multi-Epitope mRNA Vaccine Candidate for Mammarenaviruses.

Ding Zhang, Ruxia Li, Xue Fang, Zeliang Chen, Jiahai Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ding ZhangSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Ruxia LiSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Xue FangSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Zeliang ChenSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. chenzliang5@mail.sysu.edu.cn.
Jiahai LuSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. lujiahai@wmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mammarenaviruses cause serious diseases such as Lassa fever and Argentine hemorrhagic fever that threaten global public health; however, vaccines and therapeutic options remain limited. Therefore, developing a broadly effective vaccine against mammarenaviruses is a priority. In this study, we systematically analyzed the main structural protein sequences of ten mammarenaviruses. We combined antigenic epitopes from the Immune Epitope Database (IEDB) and used inverse vaccination and immunoinformatics methods to screen for highly conserved B- and T-cell epitopes with strong immunogenicity. We then added tissue plasminogen activator (tPA), which is the most effective vaccine against these pathogens. To construct a broad-spectrum multi-epitope fusion mRNA vaccine candidate, we included a tPA signal peptide, PADRE adjuvant, and linkers. The mRNA sequences were algorithm-optimized. We assessed the structural stability and immunogenicity of the candidate vaccine using molecular docking, molecular dynamics (MD) simulation, and immunosimulation. The designed vaccine had good antigenicity and structural stability, forming stable complexes with a variety of intrinsic immunoreceptors and triggering a strong, sustained, and comprehensive immune response during immunosimulation. Our study findings posit the designed vaccine as a potential broad-spectrum multi-epitope vaccine candidate against mammarenaviruses. Further real-world studies are required to validate these results.

Indexed as

Broad-spectrum vaccine candidateLASVMammarenavirusMRNA vaccineMulti-epitope vaccine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.